FMP
ResMed Inc.
RMD
NYSE
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
237.74 USD
3.6 (1.51%)
Mr. Michael J. Farrell BE, MBA, SM
Healthcare
Medical - Instruments & Supplies
NYSE
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based ...
0000943819
US7611521078
761152107
9001 Spectrum Center Boulevard
858 836 5000
US
9,980
Jun 2, 1995
0000943819
NYSE
Medical - Instrument...
Healthcare
761152107
US7611521078
US
237.74
0.76
1.13M
34.86B
-
179.42-263.05
255.4
-
-
-
-
26.65
-
https://www.resmed.com
Rating Distribution
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Stuart Mooney
8 days ago
ResMed Inc. (NYSE:RMD) is a prominent player in the healthcare sector, specializing in medical devices and cloud-based software applications. The company focuses on sleep and respiratory care, offering innovative products and services across approximately 140 countries. This extensive market reach and product innovation have contributed to a positive trend in its consensus price target over the past year. The average price target for ResMed has increased from $242.71 a year ago to $265 last mon...
Gordon Thompson
8 days ago
ResMed (NYSE:RMD) is a prominent player in the healthcare sector, specializing in the development and manufacturing of equipment for sleep disorders, such as sleep apnea. The company is set to release its quarterly earnings on April 23, 2025. Analysts predict an earnings per share (EPS) of $2.36 and revenue of approximately $1.28 billion. The anticipated EPS of $2.36 represents a 10.8% increase from the previous year, showcasing ResMed's growth trajectory. This growth is supported by a projecte...
Davit Kirakosyan
Oct 25, 2024
ResMed (NYSE:RMD) saw its shares rise 8% intra-day today following a robust first-quarter fiscal 2025 report that exceeded Street expectations. The sleep and respiratory care device maker posted adjusted earnings per share of $2.20 for the quarter, above the Street estimate of $2.05. Revenue increased by 11% year-over-year, reaching $1.22 billion and topping projections of $1.19 billion. ResMed’s operational focus contributed to notable margin gains, with gross margin expanding by 420 basis poin...
Tony Dante
Aug 28, 2024
ResMed (NYSE:RMD) has caught the attention of investors and analysts alike, being spotlighted by Zacks Investment Research as a top growth stock for those looking to invest for the long term. This recognition is not without merit; ResMed operates within the healthcare sector, focusing on developing, manufacturing, and marketing medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders. With a growing demand for healthcare solutions worldwide, Re...
FXEmpire
Aug 9, 2024
Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.
Schwab Network
Aug 8, 2024
@ResMedAmericas CEO Michael Farrell joins Oliver Renick to talk about the rise of GLP-1 drugs and its impact on the CPAP Therapy. He also discusses A.I.
Zacks Investment Research
Aug 8, 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research
Aug 2, 2024
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.